Results 1 to 10 of about 1,341,451 (156)

Residual inflammation in psoriatic arthritis patients in stable minimal disease activity [PDF]

Frontiers in Medicine, 2022
BackgroundIn psoriatic arthritis (PsA), low disease activity as defined by the Minimal Disease Activity (MDA) index is considered a good treatment target.
Pierluigi Macchioni, Antonio Marchesoni, Antonio Marchesoni, Giovanni Ciancio, Gilda Sandri, Alen Zabotti, Gentiana Vukatana, Luca Montaguti, Mariacristina Focherini, Marcello Govoni, Amelia Spinella, Nazzarena Malavolta, Francesca Zuliani, Marco Bruschi, Fabio Mascella, Carlo Salvarani, Carlo Salvarani   +16 more
doaj   +2 more sources

Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis [PDF]

Rheumatology and Therapy, 2023
Introduction The aim of this work is to characterize which Minimal Disease Activity (MDA) domains are mainly achieved, based on different treatments, in psoriatic arthritis (PsA) patients.
Silvia Scriffignano, Fabio Massimo Perrotta, Paola Conigliaro, Mario Ferraioli, Paola Triggianese, Maria Sole Chimenti, Ennio Lubrano   +6 more
doaj   +2 more sources

Minimal disease activity and associated factors in patients with psoriatic arthritis: cross-sectional study from a single center [PDF]

Rheumatology
Introduction Psoriatic arthritis (PsA) is a heterogeneous disease with various manifestations such as dactylitis, enthesitis, spondylitis, and skin involvement.
Murat Bektas, Berk Çelik, Burak İnce, Yasemin Yalçınkaya, Bahar Artım Esen, Ahmet Gül, Murat İnanç   +6 more
doaj   +2 more sources

Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning [PDF]

Arthritis Research & Therapy, 2022
Background Very few data are available on predictors of minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis (PsA). Such data are crucial, since the therapeutic measures used to change the adverse course of PsA are more likely
Rubén Queiro, Daniel Seoane-Mato, Ana Laiz, Eva Galíndez Agirregoikoa, Carlos Montilla, Hye-Sang Park, Jose A. Pinto-Tasende, Juan J. Bethencourt Baute, Beatriz Joven Ibáñez, Elide Toniolo, Julio Ramírez, Ana Serrano García, on behalf of Proyecto REAPSER Study Group   +12 more
doaj   +2 more sources

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity [PDF]

BMC Rheumatology, 2018
Background Although psoriatic arthritis is complex and involves multiple domains, recent advances in treatments have made remission or near-remission of most symptoms a potentially achievable goal for many patients.
Laura C. Coates, Ana-Maria Orbai, Akimichi Morita, Olivier Benichou, Lisa Kerr, David H. Adams, Catherine L. Shuler, Julie Birt, Philip S. Helliwell   +8 more
doaj   +2 more sources

A Proposal to Standardize Low Disease Activity Criteria in Rheumatoid Arthritis Based on the Outcome Measures in Rheumatology Minimal Disease Activity Definition [PDF]

ACR Open Rheumatology, 2020
Objective We aimed to standardize the definition of low disease activity in rheumatoid arthritis (RA) using the Outcome Measures in Rheumatology (OMERACT) group's proposed definition of minimal disease activity.
Naoto Yokogawa, Kota Shimada, Shoji Sugii, Akiko Komiya, Toshihiro Matsui, Jinju Nishino, Shigeto Tohma   +6 more
doaj   +2 more sources

Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis [PDF]

RMD Open, 2020
Objectives Methotrexate (MTX) is currently the recommended first-line therapy for treating psoriatic arthritis (PsA), despite lacking clear evidence.
Ilja Tchetverikov, J M W Hazes, Hannah den Braanker, Kim Wervers, Adriana M C Mus, Priyanka S Bangoer, Nadine Davelaar, Jolanda Luime, Marijn Vis, Erik Lubberts, Marc R Kok   +10 more
doaj   +2 more sources

Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study [PDF]

Arthritis Research & Therapy, 2017
Background Patients with psoriatic arthritis (PsA) experience functional impairment and reduced quality of life, and thus patient global assessment in PsA is explained mainly by the physical, but also by the psychological, aspect of the disease.
Rubén Queiro, Juan D. Cañete, Carlos Montilla, Miguel Abad, María Montoro, Susana Gómez, Ana Cábez, on behalf of the MAAPS study group   +7 more
doaj   +2 more sources

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study [PDF]

BMC Rheumatology
Background To explore the trajectory of, and factors contributing to, achievement of individual criteria of minimal disease activity (MDA) in patients with active psoriatic arthritis (PsA) treated with guselkumab. Methods The Phase 3, randomized, placebo-
Laura C. Coates, Proton Rahman, Philip J. Mease, May Shawi, Emmanouil Rampakakis, Alexa P. Kollmeier, Xie L. Xu, Soumya D. Chakravarty, Iain B. McInnes, Lai-Shan Tam   +9 more
doaj   +2 more sources

2-years outcomes of the treat-to-target strategy in early psoriatic arthritis

Научно-практическая ревматология, 2022
Aim – to study 2 years outcomes of the treat-to-target (T2T) strategy in early psoriatic arthritis (ePsA) patients. Material and methods. 68 (33 male/35 female) ePsA patients according to CASPAR criteria (mean age – 37.3±10.8 years; PsA duration – 11.0±9.
E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, P. O. Tremaskina, S. I. Glukhova, E. L. Nasonov   +5 more
doaj   +1 more source